Clinical Trials

Ryght joins NVIDIA Inception Program

Ryght, an innovator in generative artificial intelligence (GenAI) technology for the life science industry, today announced it has joined NVIDIA Inception, a program that supports startups with revolutionizing technological advancements in AI.

Ryght is dedicated to developing safe and secure GenAI solutions for life science companies through leveraging and optimizing multiple large language models (LLMs) to ingest real-time data streams and make actionable knowledge directly available to discovery, clinical, and commercial teams. By joining NVIDIA’s Inception program, Ryght will have access to NVIDIA’s resources and expertise, allowing it to deliver even more robust solutions.

“NVIDIA is a trailblazer in GenAI innovation. We’re excited to be among this elite group with other leading innovative companies advancing AI technologies,” stated Johnny Crupi, CTO and co-founder of Ryght. “Our GenAI platform stands at the forefront of transforming the life sciences sector by improving performance, scalability, and efficiency in labor-intensive processes. Our participation in NVIDIA Inception will catalyze our delivery of state-of-the-art software that enables these organizations to optimize their workflows with our custom copilots.  These include clinical trials document generation, gene variant research assistants, data pipelining of massive unstructured healthcare datasets, and more developed specifically for them in the areas of drug discovery, clinical research and commercial targeting.”

The NVIDIA Inception program serves as a catalyst for startups and emerging companies, providing them with unparalleled resources, support, and expertise to accelerate growth in the AI ecosystem. Through the program, Ryght gains access to a wealth of technical guidance, marketing support, and networking opportunities, empowering it to further advance its GenAI solutions.

Interested individuals can request access to a free version of Ryght, which is currently available in early preview, at The public access version will be available on March 20, 2024.

Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!

Related posts

American Society of Clinical Oncology Confers Highest Honor

PR Newswire

EmVenio Research, Health Wizz partner to reach patients across the US

PR Newswire

Avance Clinical earns 2023 Best Practices Customer Value Leadership

PR Newswire